View Older Stories View More Recent Stories
-
Eli Lilly Q4 earnings preview: Here’s what to expect
-
Erste Group Upgrades Eli Lilly (LLY) to Buy
-
Truist Securities Reiterates Buy Rating on Eli Lilly (LLY)
-
Eli Lilly & Co. (LLY) call put ratio 1.4 calls to 1 put into quarter results
-
Eli Lilly & Co. (LLY) call put ratio 1.7 calls to 1 put into quarter results
-
Eli Lilly (LLY) PT Raised to $1,038 at Truist on 'Updated FY2024 and Announced FY2025 Guidance'
-
Eli Lilly & Co. (LLY), Novo (NVO) see mid-day upside
-
Tectonic shares tumble after rival drug trial termination
-
Leerink Comments on Tectonic Therapeutics Inc. (TECX) Post Eli Lilly (LLY) Terminating volenrelaxin CKD
-
Bernstein Reiterates Outperform Rating on Eli Lilly (LLY): 'Novo Punches Back, but LLY Still a Step Ahead'
-
BofA Securities Reiterates Buy Rating on Eli Lilly (LLY)
-
Eli Lilly & Co. (LLY) Morgan Stanley sees three potential scenarios in the compounders vs. FDA over Tirzepatide
-
BofA Adjusts US 1 List
-
Eli Lilly & Co. (LLY) call put ratio 2.1 calls to 1 put
-
BofA Securities Reiterates Buy Rating on Novo Nordisk (NOVOB:DC) (NVO)
-
Leerink Partners Reiterates Outperform Rating on Eli Lilly (LLY)
-
Eli Lilly (LLY) PT Lowered to $973 at Guggenheim
-
Eli Lilly & Co. (LLY) Announces FDA Approval of Omvoh for Crohn's disease
-
Bernstein SocGen Group Reiterates Outperform Rating on Eli Lilly (LLY) Despite 'Disappointing' GLP-1 Miss
-
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)
-
Wells Fargo Reiterates Overweight Rating on Eli Lilly (LLY)
-
BofA Securities on Eli Lilly (LLY): 'a particularly good buying opportunity'
-
Citi Reiterates Buy Rating on Eli Lilly (LLY)
-
Eli Lilly & Co. (LLY) call put ratio 1.4 calls to 1 put as share price pulls back
-
Lilly (LLY) provides update on 2024 revenue guidance, announces 2025 revenue guidance
-
Eli Lilly & Co. (LLY) Asks Biden Administration to Pause Drug-price Negotiation - Bloomberg
-
Bernstein Weighs in on US Biopharma Sector in 2025; Highlights LLY as Top-pick
-
Lilly (LLY) to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program
-
Eli Lilly (LLY) in advanced talks to buy US cancer biotech for up to $2.5bn - FT
-
Medicare can now cover Eli Lilly’s (LLY) Zepbound for sleep apnea, CMS says - CNBC
-
Truist Securities Reiterates Buy Rating on Eli Lilly (LLY); ' Near-term, It's All About GLP-1/Obesity'
-
TD Cowen on Trump Tariffs and Other Risks: 'Where Does Pharma Stand?'
-
Eli Lilly & Co. (LLY) commends ITC ruling cracking down on the unlawful importation and sale of knock-off tirzepatide products that put Americans at risk
-
Piper Sandler on HGNS Devices Following Eli Lilly's Zepbound FDA Indication Approval
-
KeyBanc Weighs in on GLP-1 Injection Leaders Following Latest NVO Results
-
Eli Lilly & Co. (LLY) call put ratio 1.8 calls to 1 put after Novo Nordisk (NVO) released Cagrisema data
-
Citi Reiterates Buy Rating on Eli Lilly (LLY)
-
Viking Therapeutics (VKTX), Others Gain After Novo Nordisk (NVO) Data Falls Short of Expectations
-
Bernstein Reiterates Outperform Rating on Eli Lilly (LLY); 'Lilly's Tirzepatide is Officially "No Longer in Shortage"'
-
Eli Lilly & Co. (LLY) option IV bid into end of year
-
Hims & Hers Health (HIMS) Quickly Falls 9% after FDA Says the Obesity Drug Shortage Ended
-
Eli Lilly & Co. (LLY) Kisunla Approved in China for Treatment of Early Symptomatic Alzheimer's Disease
-
Eli Lilly & Co. (LLY) and EVA Pharma announce regulatory approval and release of locally manufactured insulin in Egypt
-
Innovent and Eli Lilly Expand Collaboration
-
Ozempic Study Found Small Number Of Patients With Vision Loss - Bloomberg
-
Eli Lilly's (LLY) Omvoh recommended by CHMP for approval in EU
-
Bernstein: 'GLP-1s vs. the Weight of the World'
-
Bernstein Sees Eli Lilly (LLY) 'In a Strong Position to Work Creatively With the New Administration'
-
Truist: 'Potential Impact of Trump's Nominees on Biopharma'
-
Eli Lilly & Co. (LLY) Reports Imlunestrant Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio
